Hua Medicine (Shanghai) Ltd. (2552.HK)
Develops oral diabetes medications and combination treatments for Chinese patients
2.35-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-26.8%
The outlook
Hua Medicine trades near its 52-week lows, well below both its 50- and 200-day moving averages, reflecting a bearish short-term trend. Analyst coverage shows a striking disconnect: the average price target implies 165% upside, yet the overall StockGlow score leans bearish at 23/100. The stock's valuation remains depressed at a trailing P/E of 1.9.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range13% of the way from its 52-week low to high
Price targetAvg target +165% vs current price
Analyst price target
~12-month · 2 analysts6.22average target+164.8% vs now
Now 2.35
Low 5.55High 6.89
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.34B
52-wk high
4.95
52-wk low
1.97
50-day avg
2.56
200-day avg
3.11
Trailing P/E
1.9